Year All20252024202320222021202020192018201720162015201420122011 Sep 15, 2020 Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Sep 8, 2020 Ardelyx to Participate in Three Upcoming Investor Conferences in September Aug 6, 2020 Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights Aug 3, 2020 Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor Jun 30, 2020 Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Jun 15, 2020 Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis Jun 9, 2020 Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 8, 2020 Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer May 26, 2020 Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference May 21, 2020 Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)